COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ICCVAM Logo

ICCVAM Biennial Report 2018-2019

ICCVAM Biennial Report 2018-2019
Menu
https://ntp.niehs.nih.gov/go/891769

Gut-endothelial Barrier Models Incorporating Microbial Colonies

AFRL has developed gut-endothelial barrier models using microfluidic technology. These gut-on-a-chip platforms emulate many of the microstructures (gut epithelial-blood endothelial interactions), morphologies (macro- and micro-villus structures), and functions of the human gut. The dynamic nature of the models provides a robust opportunity for assessing gut-blood barrier integrity, nutrient transport, and host-microbiome interactions. Moreover, a tailored oxygen environment, simulating the low-oxygen conditions seen in the human gut, promotes a more robust microbial colony inclusion. Current investigations are evaluating probiotics, cooperative microbial interactions, and complex microbial community dynamics in the gut-on-a-chip platform. The gut-on-a-chip models are also being combined with brain-on-a-chip models to allow analyses of complex molecular gut-brain axis interactions. These technologies in combination have the potential to enable assessment of operational stress and exposure outcomes due to thermal burden, nutrition, toxin ingestion and digestion, and their corresponding impact on the blood-brain barrier and neuronal activity. Furthermore, identification of molecular targets or pathways for countermeasure development can be developed, matured, and optimized in a human model prior to in vivo testing, thereby limiting animal usage and reducing the cost and time for deployment. Further validation and assessments of these promising capabilities will have to be completed before complete implementation.

Tags: